|
|||||
|
|
Modified GTX as Second-Line Therapy for Advanced Pancreatic Adenocarcinoma |
|
| Authors: | Hana Ajouz Deborah Mukherji Ali Haydar Ahmad Sharif Yakan Ahmad Saleh Elias Elias Sally Temraz Walid Faraj Mohammad Khalife Ali Shamseddine |
| Institution: | 1. Division of Hematology and Oncology, American University of Beirut Medical Center, Beirut, Lebanon 2. Division of Radiology, American University of Beirut Medical Center, Beirut, Lebanon 3. Division of General Surgery, American University of Beirut Medical Center, Beirut, Lebanon |
| Abstract: | BackgroundAdvanced pancreatic cancer remains a lethal disease with no standard treatment beyond first-line palliative chemotherapy. Gemcitabine, docetaxel, and capecitabine (GTX) is a regimen that has come into use for advanced pancreatic cancer despite a paucity of randomized data.MethodsWe have used a modified schedule of this regimen in the second-line setting aimed at biomodulating the activity of capecitabine by both docetaxel and gemcitabine. This report describes our experience with the use of modified GTX in nine patients with advanced pancreatic cancer as second-line chemotherapy.ConclusionIn our series, the median overall survival was 8 months (range 5.2–10.8). Prospective studies of this regimen in the second-line setting are warranted. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |